Entry Point Capital, LLC Syndax Pharmaceuticals Inc Transaction History

Entry Point Capital, LLC

  • $171 Million
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024
SELL
$18.82 - $23.79 $142,015 - $179,519
-7,546 Reduced 87.38%
1,090 $22.4 Million
Q1 2024

May 14, 2024
BUY
$19.71 - $24.57 $141,222 - $176,044
7,165 Added 487.08%
8,636 $206 Million
Q4 2023

Feb 14, 2024
BUY
$11.39 - $21.67 $16,754 - $31,876
1,471 New
1,471 $31.8 Million

Others Institutions Holding SNDX

# of Institutions
228
Shares Held
88.4M
Call Options Held
1.01M
Put Options Held
692K
View Full List

About Syndax Pharmaceuticals Inc

SNDX Quotes by TradingView
  • Ticker SNDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,565,200
  • Market Cap $740M
  • Description
  • Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...
More about SNDX
Track This Portfolio

Track Entry Point Capital, LLC Portfolio

Follow Entry Point Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Entry Point Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Entry Point Capital, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email